Drug-Eluting Stents Promise Limited Applicability, High Cost – Clinicians
This article was originally published in The Gray Sheet
Executive Summary
Hospitals stand to draw up to 40% less income from stenting procedures using drug-eluting stents instead of their bare metal predecessors, according to Louis Cannon, MD, Michigan Cardiovascular Institute
You may also be interested in...
Drug-Eluting Stents Will Pay Their Own Way According To SIRIUS Cost Study
The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial
Drug-Eluting Stents Will Pay Their Own Way According To SIRIUS Cost Study
The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial
Guidant Holds To 2005 Drug-Eluting Stent E.T.A. Despite Trial Delay
The start of Guidant's SPIRIT FIRST dose-selection clinical trial for the everolimus-eluting Vision stent will be delayed three to six months due to foreign-body responses detected in pre-clinical studies